Developing Novel Solutions for Brain and Inflammatory Disorders
Mission Statement

To develop novel solutions for brain and inflammatory disorders


To be a world class innovation driven biopharmaceutical company to improve the quality of life of patients


Commitment, hard work and integrity

FSD Pharma is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need.
FSD Pharma has the following 3 drug candidates in its pipeline:
A patented, proprietary neuroprotective new chemical entity (NCE) that has demonstrated in preclinical models the potential to reverse and prevent myelin degradation, an underlying cause of Multiple Sclerosis and other neurodegenerative orders
Know more
A unique psychedelic molecule currently undergoing IND enabling studies with a targeted treatment for neuropsychiatric disorders, such as Major Depressive Disorder.
Know more
An ultra micro PEA compound with the potential to address a range of inflammatory conditions. FSD-201 has completed phase 1 FDA approved trials with positive topline results, and indications for phase 2 are currently being evaluated.
Know more
Armed with a strong balance sheet, solid pipeline, and renowned clinical team, FSD intends to advance its lead drug candidates through clinical trials with the goal of providing therapies to the millions suffering from neurodegenerative and neuropsychiatric conditions.
Today there is no cure for Multiple Sclerosis (MS). FSD Pharma will attempt to change that for millions of suffering people. FSD’s proprietary compound Lucid MS has shown promising results to reverse progressive MS, in several animal models
Well positioned to advance current pipeline and aggressively pursue additional acquisitions that present compelling opportunities across the psychedelics and innovative biotech space focused on “Total Brain Health”
Renowned clinical team led by Dr. Lakshmi P. Kotra who is the recipient of the Julia Levy Award, is a Senior Scientist at Krembil Brain Institute, as well as University Health Network (UHN), and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra serves as CEO of FSD Pharma’s wholly owned subsidiary, Lucid Psycheceuticals
Current stage, growing
With experienced leadership, a diverse pipeline of clinical assets accompanied by exclusive licensing rights, and therapies advancing to treat pervasive medical conditions, like inflammation, MS and Depression, FSD Pharma is on a strong trajectory for growth
A strong balance sheet represented by no debt and approximately 50,000,000$ CAD as of May 9th 2022
Developing novel myelin repairing compounds for the treatment of neurodegenerative and neuropsychiatric diseases
Two lead candidates leverage the power of psychedelics to improve patient outcomes and address large populations ($23B multiple sclerosis market and $238B mental health market)
Lead compound, FSD 201, a proprietary ultra micro PEA compound, has shown effective anti inflammatory properties and a favorable safety profile proving potential viability for a range of conditions
Well capitalized to pursue acquisitions that advance our mission to deliver today’s most innovative treatments for Total Brain Health
Begin the process of advancing clinical trials for its compound Lucid MS, for the novel treatment of progressive MS (Multiple Sclerosis)
Begin the process of advancing clinical trials for the treatment of depression, anxiety and psychiatric disorders through its psychedelic molecule Lucid Psych
Advancement of FSD-201 for phase 2 trials
Liquidate cash position and ability to carry out its goals without the need of further financing for at least 3 plus years
Goals, strategies
focus on developing
the assets in three therapeutic areas, and acquire assets to augment the efforts to complete phase 2 clinical trials, and enter phase 3 clinical trials.
look for opportunities
to strategically integrate artificial intelligence and computer modeling and sustainability for innovative therapeutic solutions, while pursuing its mission.
continually evaluate
its direction and explore opportunities to strengthen its mission and the pipeline

Receive most valuable updates straight into your inbox



Investor Relations

      Email Alerts

      Please fill out the form below to receive company press releases via email when they occur.